Product Images Tadalafil

This is a product description of Tadalafil Tablets USP, 2.5 mg, manufactured in Israel by Teva Pharmaceutical Industries Ltd. The tablets are meant for once-daily use and are available in 30-tablet packages, which include two cards of 15 tablets each. The product is also produced for Teva Pharmaceuticals USA, Inc., based in North Wales, PA. No further information about the product is available from the given text.*

This is a medication package containing 30 tablets of Tadalafil USP 5mg, manufactured by TEVA Pharmaceuticals. The package has a GTIN code of 00800933017565 and an expiration date. The tablets should only be taken in their entire dose and kept out of reach of children. The prescribing information contains the dosage and storage instructions, and the tablets should be stored between 20-25°C (68-77°F).*

This is a medication label for tablets of Tadalafil, which comes in a 10mg box containing 30 tablets. The label provides instructions on dosing and storage temperature, as well as a warning to keep out of reach of children. There is also information on the manufacturer and the lot number.*

This is a description of a 20mg Tadalafil tablet with NDC (National Drug Code) 0093-3019-56 that should be taken according to package instructions. The tablets should be stored at a temperature between 68 to 77°F. It was manufactured in Israel by Teva Pharmaceutical Industries Ltd and is being manufactured for Teva Pharmaceuticals USA Inc located in North Wales, Pennsylvania. The packaging has the lot number 323K509810517, and the expiration date should be checked before use.*

This is a table displaying the differences between standing and supine systolic and diastolic blood pressure, as well as the time in hours. There appear to be some misspelled words ("Difersnce" and "Diference"), but this is likely due to errors in the .*

This appears to be a table showing standing and supine systolic blood pressure readings for a medication called Tacalafil (at a dose of 20 mg) combined with doxazosin (at a dose of 8 mg). There is also a comparison to placebo plus doxazosin (also at a dose of 8 mg). The table shows the readings at different time points up to 18 hours after taking the medication.*

This is a record of blood pressure measurements taken after the administration of different medications at different times. The medications administered include 20mg of tacalaf, 8mg od doxazosi, and a placebo. The text also provides the times of administration, such as 06.00, 08.0, 1800, and 0900. The record is being used to determine the effects of the medications on blood pressure.*

This is a graph showing the concentration of Tadalafil in plasma measured in mcg/L over time (in hours). The x-axis shows the time and the y-axis shows the concentration of Tadalafil. Three plots are presented, each representing a different administration protocol: a single dose of 20 mg Tadalafil (represented by the dashed line), a single dose of 5 mg Tadalafil (represented by the dotted line), and a once-daily dose of 2.5 mg Tadalafil following 5 consecutive days of administration (represented by the solid line).*

This looks like the results of a clinical trial comparing Tadalafil 5 mg to a placebo. The table shows the scores for the "1PSS Total Score" before and after treatment, with a duration of 8 to 12 weeks. Without context or further information, it is difficult to provide more details about the trial or what the "1PSS Total Score" represents.*

The information provided is a chart or table that displays the LS mean change from baseline for weeks of therapy with TadalafilFinasteride and Placebo/Finasteride at 12 and 26 weeks with a Least-Squares Treatment Difference. No further context or details are available.*

The text describes the change in IPSS total score in a clinical trial for two treatments: tadalafil 5mg and placebo. It also shows statistical significance (p<0.001) for the tadalafil treatment. The graph shows the change from baseline in the IPSS total score over a duration of treatment in weeks.*